Cathie Wood’s ARK Invest ETFs (exchange-traded funds) executed a series of trades on Friday, August 29, 2025, according to the funds’ daily disclosures. The trades reflect ARK’s continued confidence in the biotechnology sector, increasing its stake in gene-editing player Intellia Therapeutics (NTLA), while continuing to scale back on online sports betting operator DraftKings (DKNG).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wood Makes a Bold Bet on Intellia
The largest trade of the day came in Intellia Therapeutics. ARK purchased 133,015 shares of Intellia, worth about $1.54 million. This marks another step in a week of active buying, underlining her confidence in the company’s gene-editing programs.
Intellia stock has been on a strong run, climbing more than 65% in the past three months. The gains come as investors show growing interest in gene-editing companies, which are seen as front-runners in the next wave of medical innovation.
The company’s progress in advancing therapies for rare diseases aligns closely with ARK’s strategy of backing disruptive names in healthcare.
Is NTLA a Good Stock to Buy?
On TipRanks, Intellia Therapeutics stock has a Strong Buy consensus rating based on 16 Buys and three Hold ratings. The average Intellia Therapeutics price target of $29.56 implies 160.3% upside potential from current levels.
ARK Trims Stakes in DraftKings
On the selling side, Wood has steadily reduced ARK’s position in DraftKings over the past several days. On Friday, ARK sold 12,990 shares of DKNG across its ARK Innovation ETF (ARKK), ARK Next Generation Internet ETF (ARKW), and ARK Fintech Innovation ETF (ARKF), totaling $626,507.
This follows heavier selling earlier in the week, 54,679 shares on Thursday and 266,052 shares on Wednesday, showing a clear pattern of trimming the online sports betting stock.
Notably, DKNG stock has gained 34% over the past three months.
Is DraftKings a Good Stock?
On TipRanks, DraftKings stock has a Strong Buy consensus rating based on 25 Buys and two Hold ratings. The average DKNG price target of $55.29 implies 15.24% upside potential from current levels.
